+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 6Years - 17Years
All Genders
ID07027020

Randomized Trial of Intravesical Oxybutynin Versus Placebo for Treating Overactive Neurogenic Bladder in Children with Spina Bifida

Led by Central Hospital, Nancy, France · Updated on 2026-04-14

60

Participants Needed

19

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Neurogenic bladder dysfunction caused by spina bifida affects bladder control in children, leading to problems such as small bladder capacity, overactivity, incontinence, and urine evacuation issues. These complications can result in kidney failure requiring dialysis or transplantation. Current treatments include intermittent catheterization, oral anticholinergic medications like oxybutynin, botulinum toxin injections, and surgery. Oral oxybutynin can cause side effects and may be difficult for children to take, while invasive treatments like botulinum toxin injection require general anesthesia, which may affect brain development in children. This trial compares the effects of intravesical oxybutynin instillationwhere the medication is delivered directly into the bladderversus a placebo in children aged 6 to 17 years with overactive neurogenic bladder due to spina bifida who have not responded well or tolerated oral anticholinergics. Participants receive doses based on their weight, administered 2 to 3 times daily via catheterization. The study is randomized and triple-blinded, with one group receiving oxybutynin solution and the other a saline placebo. Participants are monitored over 4 weeks to assess bladder capacity and pressure, urinary incontinence, side effects, treatment usability, quality of life, and kidney ultrasound results. Assessments include bladder diary data, urodynamic tests, questionnaires, and physical exams. The study aims to delay the need for more invasive treatments in children while evaluating the safety and tolerability of intravesical oxybutynin. The total participation period is 4 weeks, with close follow-up during this time.

CONDITIONS

Brief Title

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Research Team

N

Nicolas BERTE, Dr

J

Jean-Louis LEMELLE, Pr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here